Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide. NAFLD stages range from simple steatosis (NAFL) to non-alcoholic …

The mammalian mitochondrial electron transport chain (ETC) includes complexes I‑IV, as
well as the electron transporters ubiquinone and cytochrome c. There are two electron …

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …

Liver transplantation is the ultimate method for treating end-stage liver disease. With the
increasing prevalence of obesity, the number of patients with non-alcoholic fatty liver, a …

Lifestyle modifications focused on healthy eating and regular exercise are the primary
recommendations for patients with nonalcoholic steatohepatitis (NASH). However, for …

Antioxidant nanoparticles have recently gained tremendous attention for their enormous
potential in biomedicine. However, discrepant reports of either medical benefits or toxicity …

Cardiovascular diseases (CVDs) remain a leading cause of death worldwide. Among the
major risk factors for CVD, obesity and diabetes mellitus have received considerable …

Multiphase pathological processes involve in Type 2 diabetes (T2DM)‐induced
nonalcoholic fatty liver disease (NAFLD). However, the therapies are quite limited. In the …

Oxidative stress is a critical factor in nonalcoholic fatty liver disease pathogenesis.
MicroRNA-200a (miR-200a) is reported to target Kelch-like ECH-associated protein 1 …